Menu
Recruiting NCT06528912

Standard Follow-up Program Neuro-oncology Patients (SFP Neuro-Oncology)

— Observational Neurological Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Radiotherapy.
Who it may be relevant to
Registry conditions: Neurological Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Netherlands
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Standard Follow-up Program (SFP) for Neuro-oncology Cancer Patients Treated With Radiotherapy

Overview

Standardised evaluation of baseline data regarding tumor-, patient- and treatment-characteristics as well as follow-up data regarding tumor- and clinical-outcome of neuro-oncology patients treated with radical/curative radiotherapy. Motive: Currently there is limited data on dose-effect relationships of tissues and structures in and around the brain. This lack of knowledge hampers patient selection for proton therapy, technique innovations, and accurate prediction of treatment outcome. Goal: To evaluate the selection for radiation treatment, obtain more knowledge on dose-effect relationships and enable insight in necessary treatment technique innovations that would improve treatment outcome.

Interventions

  • Other Radiotherapy
    Follow-up

Primary outcome measures

  • Treatment associated CNS toxicity [Time frame: Before start of radiation therapy, at 2,5 years; 5 years 7,5 years, 10 years and 12,5 years after completion of radiation therapy.]
  • Radionecrosis [Time frame: Before start of radiation therapy, at 2,5 years; 5 years 7,5 years, 10 years and 12,5 years after completion of radiation therapy.]
Secondary outcome measures (3)
  • Treatment associated non-CNS toxicity [Time frame: Before start of radiation therapy, at 2,5 years; 5 years 7,5 years, 10 years and 12,5 years after completion of radiation therapy]
  • Overall survival [Time frame: Before start of radiation therapy, at 2,5 years; 5 years 7,5 years, 10 years and 12,5 years after completion of radiation therapy.]
  • Progression free survival [Time frame: Before start of radiation therapy, at 2,5 years; 5 years 7,5 years, 10 years and 12,5 years after completion of radiation therapy]

Eligibility criteria

Inclusion criteria

  • Patient with neuro-oncological cancer
  • Patient receiving a radiotherapy dose XXX Gy

Exclusion criteria

  • Failure to comply with any of the inclusion criteria

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Netherlands · 1 center
  • UMCG — Groningen

Identifiers

NCT: NCT06528912 · SFP Neuro-Oncology

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗